Day: November 7, 2022

WASHINGTON — Although adenovirus infection has been widely implicated in an outbreak of acute, severe hepatitis in children, data presented at The Liver Meeting found no “singular definitive etiology” for these cases.“Beginning in October 2021, there were multiple clusters identified across the world of young children having a severe acute hepatitis and liver failure,” Rohit…

WASHINGTON — Patients with cirrhosis who received three doses of the COVID-19 mRNA vaccine, demonstrated an 80% reduced risk for SARS-COV-2 infection, symptomatic COVID-19, and moderate/severe/critical COVID-19, noted a presenter here.“When the FDA approved the booster or a third dose of the [COVID-19] vaccine, they initially approved it for solid organ transplant recipients, patients on…

WASHINGTON — Preliminary results showed combined VIR-2218 and VIR-3434 therapy reduced hepatitis B surface antigen with mild adverse events among a small subset of patients with chronic HBV infection.“This audience is well aware of the current standard of care and the long-term issues regarding cost, potential risk of breakthrough and toxicity,” Edward J. Gane, MD,…

WASHINGTON — Patient survival was no different for living donor liver transplant recipients with a MELD score greater than 25 compared with those with lower MELD scores, according to data presented at The Liver Meeting.“Historically, in the United States especially, living donor transplantation has been offered to patients with low or moderate MELD,” Benjamin E….

WASHINGTON D.C. — In a Healio video exclusive, Ron Cooper, CEO of Albireo Pharma, highlighted positive top-line safety and efficacy results of Bylvay for the treatment of Alagille syndrome in patients from birth to early adulthood.In the double-blind, placebo-controlled phase 3 ASSERT trial, patients were randomized 2:1 to receive once-daily 120 g/kg Bylvay (odevixibat, Albireo),…